Entera Bio Ltd (NASDAQ:ENTX) shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint.
According to Entera, EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis patients.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Entera Bio is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with a significant unmet medical need.
Trading has been halted three times as of 10:10 a.m. ET. Entera Bio shares are trading higher by 103.47% at $8.22 at the time of publication.